Serialization Capabilities Now Operational at Lonza Edinburgh Facility for Liquid-Filled Hard Capsules
(WorldNews Switzerland)

Counterfeit and diverted medicines are a growing threat to patients Investment in former Capsugel site improves anti-counterfeiting security for Lonza`s global supply chain Lonza customers are already benefiting from increased protection for their patients, well ahead of U.S. and EU legislation implementation Basel, Switzerland, 14 December 2017- Lonza announced today that its integrated development and manufacturing site for biopharmaceutical liquid-filled hard capsules in Edinburgh (UK) has new anti-counterfeiting security capabilities in place and is in full compliance with EU and U.S. regulatory requirements for serialization. Lonza`s customers will benefit from this investment to secure...